<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01438073</url>
  </required_header>
  <id_info>
    <org_study_id>2011-P-001564</org_study_id>
    <nct_id>NCT01438073</nct_id>
    <nct_alias>NCT01862094</nct_alias>
  </id_info>
  <brief_title>Elucidating Kisspeptin Physiology by Blocking Kisspeptin Signaling</brief_title>
  <official_title>Elucidating Kisspeptin Physiology by Blocking Kisspeptin Signaling</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Massachusetts General Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Massachusetts General Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators are looking for subjects to complete a study on the role of kisspeptin in&#xD;
      the reproductive system. Kisspeptin is a naturally occurring hormone in humans that tells the&#xD;
      body to produce other reproductive hormones. However, giving someone a continued amount of&#xD;
      kisspeptin over a period of time can have the opposite effect and tell the body to, for a&#xD;
      short time, stop making hormones needed for reproduction. By giving 24-hour infusions of&#xD;
      kisspeptin, the investigators hope to learn more about the role kisspeptin has in the way&#xD;
      bodies function normally and the role it has in conditions that affect the reproductive&#xD;
      system.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Please contact study staff for a detailed description.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 2011</start_date>
  <completion_date type="Anticipated">September 2023</completion_date>
  <primary_completion_date type="Anticipated">September 2023</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Average difference in Luteinizing Hormone (LH) concentration at the beginning and end of kisspeptin infusion</measure>
    <time_frame>24 hours</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Average difference in testosterone concentration at the beginning and end of kisspeptin infusion (males)</measure>
    <time_frame>24 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Average difference in estradiol concentration at the beginning and end of kisspeptin infusion (females)</measure>
    <time_frame>24 hours</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">411</enrollment>
  <condition>Hypogonadotropic Hypogonadism</condition>
  <condition>Healthy Postmenopausal Women</condition>
  <condition>Agonadism</condition>
  <arm_group>
    <arm_group_label>kisspeptin, GnRH</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>24-hour continuous intravenous infusion of kisspeptin 112-121 (12.5-40 mcg/kg/h), single intravenous dose of kisspeptin 112-121 (0.313-13.19 mcg/kg), and single bolus of GnRH (gonadotropin-releasing hormone) (2.5-250 ng/kg)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>kisspeptin 112-121</intervention_name>
    <description>24-h continuous intravenous infusion of kisspeptin 112-121 (12.5-40 mcg/kg/h), single intravenous dose of kisspeptin 112-121 (0.313-13.19 mcg/kg)</description>
    <arm_group_label>kisspeptin, GnRH</arm_group_label>
    <other_name>metastin 45-54</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GnRH</intervention_name>
    <description>Single intravenous dose of GnRH (2.5-250 ng/kg)</description>
    <arm_group_label>kisspeptin, GnRH</arm_group_label>
    <other_name>gonadotropin-releasing hormone</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        A. Healthy Subjects&#xD;
&#xD;
        All healthy subjects will meet the following criteria:&#xD;
&#xD;
          -  normal puberty with respect to onset and pace,&#xD;
&#xD;
          -  no difficulty with blood draws,&#xD;
&#xD;
          -  no prescription medications for at least 2 months with the exception of asthma&#xD;
             medication (albuterol only), hypercholesterolemia medication and psychiatric&#xD;
             medication,&#xD;
&#xD;
          -  no illicit drug use or excessive alcohol consumption (&gt;10 drinks/week),&#xD;
&#xD;
          -  no history of a medication reaction requiring emergency medical care,&#xD;
&#xD;
          -  normal physical exam and laboratory studies within protocol reference ranges.&#xD;
&#xD;
        Additional criteria based on subject population:&#xD;
&#xD;
          1. Healthy Men:&#xD;
&#xD;
               -  between 21 and 40 years old,&#xD;
&#xD;
               -  normal erectile and ejaculatory function, no history of reproductive disorders,&#xD;
&#xD;
               -  testicular volume &gt;15 ml.&#xD;
&#xD;
          2. Healthy women:&#xD;
&#xD;
               -  between 21 and 40 years old,&#xD;
&#xD;
               -  not breastfeeding or pregnant,&#xD;
&#xD;
               -  menstrual cycles between 25 and 35 days in duration with no more than 5 days&#xD;
                  variability in cycle duration,&#xD;
&#xD;
               -  no evidence for androgen excess (hirsutism or acne),&#xD;
&#xD;
          3. Healthy postmenopausal women:&#xD;
&#xD;
               -  between 48 and 60 years old,&#xD;
&#xD;
               -  no menstrual periods within the last year,&#xD;
&#xD;
               -  previous history of menstrual cycles between 25 and 35 days in duration, with no&#xD;
                  more than 5 days variability in cycle duration,&#xD;
&#xD;
               -  if applicable, able to undergo washout from hormone therapy,&#xD;
&#xD;
               -  no evidence for androgen excess (hirsutism or acne),&#xD;
&#xD;
               -  negative screening for Factor V Leiden for those who might receive estradiol&#xD;
                  treatment as a part of this study.&#xD;
&#xD;
        B. Subjects with Reproductive Disorders&#xD;
&#xD;
        All subjects with reproductive disorders will meet the following criteria:&#xD;
&#xD;
          -  all medical conditions stable and well controlled, medications allowed include asthma&#xD;
             medication (albuterol only), hypercholesterolemia medication and psychiatric&#xD;
             medication,&#xD;
&#xD;
          -  no medications known to affect reproductive endocrine function for at least 2 months&#xD;
             except for medications used to treat the subject's reproductive condition,&#xD;
&#xD;
          -  no history of a medication reaction requiring emergency medical care,&#xD;
&#xD;
          -  no illicit drug use or excessive alcohol consumption (&gt;10 drinks/week),&#xD;
&#xD;
          -  for women, not breastfeeding or pregnant,&#xD;
&#xD;
          -  if applicable, able to undergo appropriate washout from hormone therapy,&#xD;
&#xD;
          -  normal physical exam and laboratory studies within protocol reference ranges,&#xD;
&#xD;
        Additional criteria based on subject population:&#xD;
&#xD;
          1. Men and women with hypogonadotropic hypogonadism,&#xD;
&#xD;
               -  18 years or older,&#xD;
&#xD;
               -  Confirmed diagnosis by low sex steroids in the setting of low or inappropriately&#xD;
                  normal gonadotropins,&#xD;
&#xD;
               -  If needed, additional labs and imaging tests may be performed.&#xD;
&#xD;
          2. Agonadal men,&#xD;
&#xD;
               -  Between 18 and 60 years old.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Stephanie B Seminara, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Massachusetts General Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Study Coordinator</last_name>
    <phone>617-726-8484</phone>
    <email>MGHKisspeptinResearch@partners.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Margaret Lippincott, M.D.</last_name>
    <phone>617-726-8434</phone>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Stephanie B Seminara, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Yee-Ming Chan, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Margaret Lippincott, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>August 24, 2011</study_first_submitted>
  <study_first_submitted_qc>September 20, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 21, 2011</study_first_posted>
  <last_update_submitted>July 1, 2021</last_update_submitted>
  <last_update_submitted_qc>July 1, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 2, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Massachusetts General Hospital</investigator_affiliation>
    <investigator_full_name>Stephanie B. Seminara, MD</investigator_full_name>
    <investigator_title>Chief, Reproductive Endocrine Unit; Professor of Medicine, Harvard Medical School; Director, Harvard Reproductive Endocrine Sciences Center</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypogonadism</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hormones</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

